Edgar Filing: Lauterbach Sandra Leigh - Form 4

Lauterbach S Form 4 July 18, 2012									
EORM	Л								PPROVAL
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287	
Check thi if no long subject to Section 14 Form 4 or	IGES IN BENEFICIAL OWNERSHIP OF SECURITIES				Expires: January 31 200 Estimated average burden hours per				
Form 4 or Form 5 obligations may continue.response0.5See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.5									
(Print or Type R	Responses)								
1. Name and A Lauterbach S	er Name and Ticker or Trading x BioTherapeutics, Inc. [PLX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (M	iddle) 3. Date of	f Earliest Tra	ansaction			(Chec	к ан аррисаве	;)
			(Month/Day/Year) 07/16/2012			Director 10% Owner X Officer (give title Other (specify below) VP, Sales & Commercial Affairs			
(Street) 4. If Ame			endment, Date Original			6. Individual or Joint/Group Filing(Check			
BOSTON, N				_X_Form filed by 0 Form filed by M	One Reporting Person More than One Reporting				
(City)		Zip) Tab		• • •					
1.Title of Security	2. Transaction Date (Month/Day/Year)	a I - Non-Derivative Securities Acquired 3. 4. Securities Acquired Transaction(A) or Disposed of				quired, Disposed of, or Beneficially Owned5. Amount of Securities6. Ownership Form: Direct7. Nature of Form: Direct			
(Instr. 3) any			Code (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price			Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
Common Stock	07/16/2012		A	20,000	A	\$ 0	20,000 (1)	Ι	By Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Under Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Lauterbach Sandra Leigh - Form 4

Reporting Owners

Reporting Owner Name / Add	lress	Relationships							
	Director	10% Owner	Officer	Other					
Lauterbach Sandra Leigh 263 CYPRESS STREET BOSTON, MA 02445			VP, Sales & Commercial Affairs						
Signatures									
/s/ Yossi Maimon, POA	07/18/2012								
**Signature of Reporting	Date								

Explanation of Responses:

Person

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., issued under its 2006 Stock Incentive Plan, as amended June 17, 2012. The restricted shares vest in 12 equal quarterly increments over a three-year period, commencing on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.